Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product in six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly broadening the company's international footprint. These partnerships were concluded with six separate companies, each responsible for an individual market, and include minimum purchase quantities. Based on these contracts, Viromed anticipates additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It targets hospitals, private practice physicians, and surgically active medical specialists. The device has been well-received in the DACH region, and these new agreements mark a strategic move to penetrate Southern and South-Eastern Europe as well as the Middle East.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, stated, "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion builds on Viromed's existing international network. The company already holds numerous distribution and marketing partnerships, including an exclusive distribution agreement with the Korean company UMECO covering ten Asian countries, and a distribution partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. These agreements have been instrumental in establishing Viromed as a key player in the global medical technology sector.
The importance of these new partnerships lies in their potential to drive significant revenue growth and market penetration. By securing minimum purchase quantities, Viromed ensures a steady demand for ViroCAP®, which is expected to contribute to the company's financial stability and long-term growth. The expansion into these new regions also diversifies Viromed's market presence, reducing reliance on any single geographic area.
Furthermore, the timing of these agreements is strategic. As the healthcare industry increasingly adopts advanced technologies, the demand for non-invasive and effective treatment options like cold plasma is on the rise. ViroCAP® offers a unique solution for skin conditions, which are common in both medical and aesthetic practices. The device's portability and ease of use make it an attractive option for healthcare providers across different settings.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products. Its operating business, conducted through its wholly-owned subsidiary Viromed Medical GmbH, centers on the distribution of innovative cold plasma technology. The company aims to further advance the use of this technology in medicine and realize its growth potential.
The new distribution partnerships are a testament to Viromed's commitment to expanding its global reach and establishing a strong presence in emerging markets. With additional partnerships expected in the coming weeks, the company is poised for continued growth and innovation in the medical device industry.
